Loxo founder Josh Bilenker, Novartis oncology leader Jeff Engelman join forces to debut cancer R&D player
Josh Bilenker has been busy since leaving Eli Lilly at the end of January.
Earlier on Monday he put out word on LinkedIn that he and Novartis’ global head of oncology, Jeff Engelman, have launched a new cancer R&D biotech — and they’ve already banked the A round to fund ops.
In a statement, the two founders noted that they were going after difficult but validated molecular targets in oncology, zeroing in on proteins such as kinases and other enzymes that can now be pipeline fodder due to a laundry list of every buzzy biotech tool you can throw in a paragraph: CRISPR, machine learning/AI, X-ray crystallography and so on.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.